Epizyme shares slump as cancer drug data update disappoints
Analysts hate to be disappointed, and that’s just what Epizyme $EPZM accomplished this morning as it updated its camp followers with the latest data on tazemetostat for diffuse large B-cell lymphoma.
Initially, observers had been pleased by the 40% overall response rate that researchers had been tracking on DLBCL for its EZH2 inhibitor. Then this morning the company provided an update on their Phase II with more patients in the mix, and the ORR dropped to 29%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.